

Dakai Liu et al.

Serial No.: 08/822,963

Filed: March 21, 1997

Page 4 [Submission (Amendment) Accompanying

Request for Continued Examination (RCE) – January 11, 2002]

-- 94. (NEW) The vector of claim 91, further comprising a native or non-native viral vector terminator or processing signal or segment thereof, or both. --

-- 95. (NEW) The vector of claim 94, wherein said native or non-native viral vector terminator or processing signal or segment thereof, or both, have been modified. --

-- 96. (NEW) The vector of claim 91, wherein said non-deletion modification comprises a substitution of a native sequence segment with a non-retroviral sequence segment. --

-- 97. (NEW) The vector of claim 91, wherein said non-deletion modification comprises a substitution of a native sequence segment with a non-retroviral sequence segment, said non-retroviral sequence segment not being derived from promoter/enhancer sequences of a retrovirus. --

-- 98. (NEW) The vector of claim 91, wherein said non-deletion modification comprises a mutation selected from the group consisting of a point mutation, an insertion, a substitution and a combination of any of the foregoing. --

-- 99. (NEW) The vector of claim 91, wherein said viral vector is a retrovirus. --

-- 100. (NEW) The vector of claim 94, wherein said terminator, or said processing signal, or both, include a polyadenylation signal. --

Enz-56(C)

-- 101. (NEW) The vector of claim 95, wherein said modified terminator, or said modified processing signal, or both, include a polyadenylation signal. --

-- 102. (NEW) The vector of claim 91, further comprising a segment of a viral vector terminator or a segment of a processing signal, or both a viral vector terminator and a segment of a processing signal. --

-- 103. (NEW) The vector of claim 92, wherein the function of said one or more promoter/enhancers regions have been reduced, inhibited or eliminated. --

-- 104. (NEW) The vector of claim 92, wherein said one or more native or non-native promoter/enhancer regions produce an RNA lacking a polyadenylation signal. --

-- 105. (NEW) The vector of claim 69, wherein said one or more native or non-native promoter/enhancer regions are selected from the group consisting of a regulatory portion of genes, said genes being selected from the group consisting of snRNA, tRNA, rRNA, and a combination of any of the foregoing. --

-- 106. (NEW) The vector of claim 105, further comprising one or more genes or gene segment sequences of said snRNA, tRNA or rRNA gene or genes. --

Dakai Liu et al.

Serial No.: 08/822,963

Filed: March 21, 1997

Page 6 [Submission (Amendment) Accompanying
Request for Continued Examination (RCE) - January 11, 2002]

-- 107. (NEW) The vector of claim 105, wherein said snRNA is selected from the group consisting of U1, U2, U3, U4, U5, U6, U7, U8, U9, U10, U11 and a combination of any of the foregoing. --

-- 108. (NEW) The vector of claim 106, wherein said snRNA is selected from the group consisting of U1, U2, U3, U4, U5, U6, U7, U8, U9, U10, U11 and a combination of any of the foregoing. --

-- 109. (NEW) The vector of claim 93, wherein said modification comprises a substitution or replacement of or addition to said one or more native or non-native promoter/enhancer regions with an exogenous gene or an exogenous nucleic acid sequence. --

-- 110. (NEW) A process for producing the viral vector or viral vector nucleic acid or nucleic acid construct that comprises a viral vector nucleic acid sequence of claim 91, said process comprising the steps of:

providing said vector of claim 91; and

introducing said vector into a packaging cell line or a packaging cell line under conditions to produce said viral vector or said viral vector nucleic acid. --

-- 111. (NEW) The process of claim 110, wherein either said providing step or said introducing step, the nucleic acid construct has been modified in a non-native promoter/enhancer region. --

Enz-56(C)

Dakai Liu et al.

Serial No.: 08/822,963

Filed: March 21, 1997

Page 7 [Submission (Amendment) Accompanying

Request for Continued Examination (RCE) - January 11, 2002]

-- 112. (NEW) The process of claim 110, wherein said nucleic acid construct, when introduced into said packaging cell or packaging cell line, stably integrates into the genome of said packaging cell or said packaging cell line. --

-- 113. (NEW) The process of claim 110, wherein said nucleic acid construct has been introduced by means of an episome. --

-- 114. (NEW) The process of claim 110, wherein said nucleic acid construct has been introduced by means of transient expression. --

* * * * *